Strength of Incepta:

• Wide Range of products: Incepta Pharmaceuticals has the second-largest product line in the Bangladeshi Pharmaceuticals Industry. They are manufacturing more than 600 types of products for the local and international markets including oral cholera vaccines, vaccines for influenza, measles, rubella and Hepatitis B.

• Distribution Channel:  They have a total of 28 depots all over Bangladesh. This is generously higher than their competitors.

• Technological Advancement:  Incepta is one of the finest and most technologically advanced pharmaceuticals company in Bangladesh. Incepta is the only Pharmaceuticals Company in Bangladesh which has separate Biotech products, Human vaccines, Monoclonal Antibodies, Hormones, Natural Products, Animal Health Products, Hygiene Products, and Hospital Devices. They also have a separate company for Hygiene & Vaccine Products.

• Exports: Incepta Pharmaceuticals Ltd Exporting its products to 67 countries across the world.

• Facilities: Incepta Has 3 Manufacturing sites in Bangladesh at Savar, Zirabo and Dhamrai and they also have 17 factories and research facilities.

• Annual Turnover: According to Daily Star (January 10, 2021), Incepta’s Annual Turnover was 2,755 Crore, which is the 2nd largest in Bangladeshi Pharmaceuticals Industry.

Weakness of Incepta:

• Incepta is a concern of the Impress group, and their nearest competitors are the concern of Square and Beximco Group. Square and Beximco both are dominating Bangladeshi different industries.  That’s why Incepta is getting lower brand value than its nearest competitors. 

• Square Pharmaceuticals Already started manufacturing their products outside of Bangladesh, Incepta will be losing competitive advantages for this in the international market, because it will help their competitor to minimize their costs and offer a better price in International Markets.

Opportunities of Incepta:

• As Bangladesh is an overpopulated country and the rate is always getting higher, the demand for drugs and their medical needs are also increasing.
• Pharmaceuticals Industry has tremendous export potential in Bangladesh. Overall export earnings from the Pharmaceuticals industry are USD 136 Million in the fiscal year of 2019-20.   Over the past five years, the pharmaceutical industry in Bangladesh has been growing at a CAGR of 15.6% every year. 

Threats of Incepta:

• With the implementation of uniform patent law from January 01, 2015, new drugs patented thereafter will be protected for 20 years across all the signatory countries. MNCs, at the same time, will be more inclined to introduce the latest drugs from the patent portfolio, a big threat for local generic produces, Local players will have to compete directly with the MNCs as they will longer be allowed to override patent law (M. G. Mostofa, Scribd, 2013)